SK Biopharmaceuticals, a prominent South Korean pharmaceutical company with a growing commercial footprint in the United States, has finalized a definitive agreement to in-license opakalim, a late-stage epilepsy drug candidate from Biohaven. The deal, valued at up to $795 million including upfront payments and potential milestones, represents a significant move for the Seoul-based drugmaker as it seeks to diversify its central nervous system (CNS) portfolio and solidify its position in the competitive U.S. neurology market. Under the terms of the agreement, SK Biopharmaceuticals acquires the global rights to develop and commercialize opakalim, a novel Kv7 potassium channel activator designed to treat seizure disorders through a mechanism of action distinct from current standard-of-care therapies.
The financial structure of the transaction involves an immediate commitment of $400 million from SK Biopharmaceuticals. This upfront sum is divided into a $350 million payment due upon the closing of the deal, followed by an additional $50 million payment to be issued one year later. Beyond the initial capital, Biohaven is eligible to receive up to $395 million in various clinical, regulatory, and commercial milestone payments. The agreement also stipulates that Biohaven will receive tiered royalties on net sales of opakalim should the drug receive regulatory approval and reach the market. A portion of these proceeds will be shared with Knopp Biosciences, the original developer of the molecule and the progenitor of Channel Bio, which Biohaven acquired in 2022 to secure the opakalim program.
The Science of Opakalim: A New Mechanism for Seizure Control
Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures, which are caused by abnormal, excessive electrical activity in the brain. This activity often stems from an imbalance in the flow of charged ions across cell membranes. While many existing anti-seizure medications (ASMs) target sodium or calcium channels, or modulate neurotransmitters like GABA and glutamate, opakalim utilizes a different approach. It acts as a selective activator of the Kv7 (KCNQ) potassium channel.
The Kv7.2 and Kv7.3 potassium channels play a critical role in maintaining the resting membrane potential of neurons. When these channels are open, they allow potassium ions to exit the cell, which serves as a "molecular brake" to suppress neuronal over-excitability. By activating these channels, opakalim aims to stabilize the electrical environment of the brain and prevent the runaway signaling that leads to seizures.
Opakalim, previously known as BHV-7000, was specifically engineered to avoid the off-target effects associated with earlier generations of Kv7 activators. Previous attempts to target this pathway often resulted in adverse events such as dizziness, somnolence, and urinary retention due to the activation of Kv7 channels in non-target tissues. Biohaven’s development of opakalim focused on achieving high selectivity for the Kv7.2/7.3 subtypes, which are primarily expressed in the central nervous system, potentially offering a "cleaner" safety profile for patients with focal onset epilepsy.
Strategic Realignment and Clinical Timeline
The acquisition of opakalim comes at a pivotal time for both companies. For SK Biopharmaceuticals, the move builds upon the success of its flagship product, cenobamate (marketed in the U.S. as Xcopri). Cenobamate, which received FDA approval in 2019, has seen robust adoption as a treatment for partial-onset seizures in adults. However, cenobamate primarily works by inhibiting sodium currents and modulating GABAA receptors. Adding a Kv7 activator like opakalim allows SK Biopharmaceuticals to offer a complementary therapy that can be used in patients who may not respond adequately to existing ion-channel modulators.
The clinical timeline for opakalim is aggressive. The drug is currently in Phase 3 testing for focal onset epilepsy, the most common type of epilepsy in adults. SK Biopharmaceuticals expects to see preliminary Phase 2/3 data by the end of 2024. A second major data readout is anticipated in 2028. If the clinical trials demonstrate the requisite safety and efficacy to satisfy the U.S. Food and Drug Administration (FDA), SK Biopharmaceuticals plans to launch the drug in the U.S. market in 2029.
Donghoon Lee, CEO of SK Biopharmaceuticals, emphasized that the acquisition is a cornerstone of the company’s broader strategy to become a global leader in the CNS space. "This clearly signals that our company has stepped into the major leagues across all dimensions," Lee stated during the announcement. He noted that the deal enables the company to leverage its existing U.S. commercial infrastructure, operated through its New Jersey-based subsidiary, SK Life Science, to market multiple therapies simultaneously.
Biohaven’s Strategic Pivot and Financial Health
For Biohaven, the out-licensing of opakalim represents a strategic decision to raise non-dilutive capital while focusing internal resources on other high-potential areas of its pipeline. As of mid-2024, Biohaven reported a cash position of approximately $270.5 million. The $400 million infusion from SK Biopharmaceuticals significantly bolsters the company’s balance sheet without requiring the issuance of new equity.
Industry analysts have noted that Biohaven has a history of monetizing its neurological assets to fund broader research and development. In 2022, the company sold its migraine franchise, including the blockbuster drug Nurtec ODT, to Pfizer for $11.6 billion. The current iteration of Biohaven was spun off from that deal, retaining a pipeline of early-to-late-stage candidates.
With the opakalim deal, Biohaven is shifting its focus toward immunology and metabolic health. One of the company’s most anticipated programs is taldefgrobep alfa, a fusion protein licensed from Bristol Myers Squibb. Taldefgrobep alfa is being studied as a potential treatment for obesity; it is designed to block myostatin and activin signaling, which may help prevent muscle wasting—a common side effect of GLP-1 weight-loss drugs—while simultaneously reducing fat accumulation. Preliminary Phase 2 data for this program are expected by the end of 2024. Additionally, Biohaven is advancing BHV-1300 for Graves’ disease and BHV-1400 for immunoglobulin A (IgA) nephropathy.
Competitive Landscape and Market Analysis
The market for focal onset epilepsy treatments is lucrative but highly competitive. Analysts from William Blair have projected that peak sales for novel drugs in this indication could range from $2 billion to $4 billion annually. However, opakalim faces stiff competition from other Kv7-targeting candidates currently in development.
Xenon Pharmaceuticals is a primary competitor with its lead candidate, azetukalner. In Phase 2 trials, azetukalner demonstrated a 42.7% placebo-normalized improvement in median monthly seizure frequency. Analysts have described these results as "truly remarkable," particularly given the refractory nature of the patient population studied. Xenon’s drug is also in late-stage development, meaning the race to be the first-in-class Kv7 activator on the market is intensifying.
Furthermore, Jazz Pharmaceuticals recently entered the fray by licensing SAN2355 from Saniona. SAN2355 is a preclinical small molecule designed to selectively activate Kv7.2 and Kv7.3. While opakalim and azetukalner are further ahead in the clinic, the entry of Jazz Pharmaceuticals underscores the industry-wide interest in the Kv7 mechanism.
The debate among investors regarding opakalim centers on its safety profile. Marc Goodman, an analyst at Leerink Partners, noted that opakalim is perceived to have a "cleaner" safety profile compared to Xenon’s drug. While some view this as an advantage that could lead to better patient compliance and fewer side effects, others suggest that a cleaner safety profile might indicate weaker target engagement, potentially leading to lower efficacy. The upcoming Phase 2/3 data will be critical in resolving this debate and determining whether opakalim can differentiate itself on safety or if it can match the high efficacy bar set by Xenon.
Broader Implications for the Pharmaceutical Industry
The deal between SK Biopharmaceuticals and Biohaven reflects several broader trends in the global pharmaceutical industry. First, it highlights the increasing prominence of South Korean drugmakers on the international stage. By establishing a strong commercial presence in the U.S. and actively pursuing high-value licensing deals, companies like SK Biopharmaceuticals are transitioning from regional players to global innovators.
Second, the transaction illustrates the ongoing shift toward precision medicine in neurology. The focus on specific ion channel subtypes like Kv7.2 and Kv7.3 represents a move away from broad-spectrum "dirty" drugs that affect multiple systems, toward highly targeted molecules that minimize systemic side effects.
Finally, the deal underscores the high demand for non-dilutive financing in the biotech sector. In an environment where traditional equity markets can be volatile, out-licensing late-stage assets to larger partners allows biotech companies to sustain their operations and fund diverse pipelines without diluting shareholder value.
As the epilepsy treatment landscape evolves, the success of opakalim will depend heavily on the strength of its upcoming clinical data. If SK Biopharmaceuticals can prove that the drug offers a superior balance of safety and efficacy, it could become a foundational therapy for millions of patients worldwide who struggle with treatment-resistant seizures. For now, the pharmaceutical industry will be watching closely as the end-of-year data readouts approach, signaling the next chapter for both SK Biopharmaceuticals and the future of epilepsy care.
